SecBot SecBot
SECBOTREPLAY Home › Report › AXSM

AXSM · Axsome Therapeutics announced FDA approval of AUVELITY for agitation…

Axsome Therapeutics, Inc. · PRESS-RELEASE filed May 1, 2026 at 07:15 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed May 1, 2026 at 07:15 ET

Axsome Therapeutics announced FDA approval of AUVELITY for agitation associated with Alzheimer's disease dementia, a major label expansion for an already-approved MDD drug. This addresses a large, underserved patient population (up to 76% of >7M Alzheimer's patients) with no approved treatment, creating a significant commercial opportunity.

  • FDA approved AUVELITY for agitation associated with dementia due to Alzheimer's disease, a first-in-class treatment targeting NMDA and sigma-1 receptors.
  • Alzheimer's disease affects >7 million people in the U.S., with agitation reported in up to 76% of patients.
  • AUVELITY was initially approved for MDD in 2022 and is protected by a robust patent estate extending to at least 2043.
  • The approval addresses a condition with no currently approved treatment, representing a significant unmet medical need.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access